/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION
MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES
LAWS./
VICTORIA, Jan. 12, 2017 /CNW/ - Emerald Health
Therapeutics Inc. (TSXV: EMH) ("Emerald" or the "Company")
announces it has filed a base shelf prospectus (the "Prospectus")
with the securities regulatory authorities in the provinces of
British Columbia and Alberta.
The Prospectus, when made final and effective, will enable the
Company to make offerings of up to $50,000,000 of common shares, preferred shares,
debt securities, warrants, units or subscription receipts of the
Company or a combination thereof from time to time,
separately or together, in amounts, at prices and on terms to
be determined based on market conditions at the time of the
offering and as set out in an accompanying prospectus
supplement, during the 25-month period that the Prospectus, when
made final, remains effective. The specific terms of any future
offering will be established in a prospectus supplement to the
Prospectus, which supplement will be filed with the applicable
Canadian securities regulatory authorities. The net proceeds from
any sale of any securities will be used for purposes as set out in
the applicable Prospectus supplement.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which an offer,
solicitation or sale would be unlawful prior to registration or
qualifications under the securities laws of any such
jurisdiction.
A copy of the Prospectus can be found under the Company's
profile on sedar.com or may be obtained from the Company upon
written request from the contact below.
ON BEHALF OF THE BOARD
Jim Heppell
Lead Director
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics Inc. is a Licensed Producer under
the Access to Cannabis for Medical Purposes Regulations (the
"ACMPR"), authorized to cultivate and sell both dried medical
cannabis flower and medical cannabis oils in Canada. Emerald currently operates out of an
indoor facility in Victoria, British
Columbia, with plans for a purpose built hybrid greenhouse
expansion on 32 acres in metro Vancouver. Emerald prides itself on being one
of Canada's most medically focused
producers with one of the industry's most qualified management
teams with regard to pharmaceutical drug discovery, development and
distribution. We aim to capture unique niches of both the medical
and future recreational cannabis markets through proprietary
strains, defensible intellectual property, and superb client and
consumer experience.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements. Forward-looking statements include, but are not
limited to, statements regarding the filing and effectiveness of
the final base shelf prospectus; the filing and effectiveness of
any potential prospectus supplement and the amount and terms of any
securities to be offered.
Emerald Health Therapeutics Inc. does not intend, and does not
assume any obligation, to update these forward-looking statements
except as required by law. These forward-looking statements involve
risks and uncertainties relating to, among other things, the timing
and filing of the final base shelf prospectus; the potential
offering of any securities by the Company; uncertainty with
respect to the completion of any future offering; the ability to
obtain applicable regulatory approval for any contemplated
offerings ; the ability of the Company to negotiate and
complete future funding transactions; variations in market
conditions; and other risk factors described in the Prospectus and
the Company's other filings with the applicable Canadian securities
regulators, which may be viewed at www.sedar.com. Actual
results may differ materially from those expressed or implied by
such forward-looking statements.
SOURCE Emerald Health Therapeutics, Inc.